Table Graph
      published meta-analysis   sensitivity analysis   studies

standard of care in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCORIMUNO-TOCI-ICU (Group 2), 2020 (REV) 1.56 [0.56; 4.40] Declercq J (COV-AID), 2021 (REV) 0.98 [0.38; 2.57] EU-CTR2020-001375-32 (PreToVid), 0 (REV) 1.69 [0.95; 3.04] EU-CTR2020-001748-24 (ImmCoVA), 0 (REV) 0.80 [0.10; 6.22] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 (REV) 1.94 [0.04; 106.66] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 (REV) 14.29 [1.14; 179.57] NCT04577534 (COVIDSTORM), 0 (REV) 2.04 [0.04; 108.96] Rutgers, 2021 (REV) 1.70 [0.94; 3.06] Talaschian, 2021 (REV) 0.64 [0.14; 2.92] Veiga, 2021 (REV) 0.37 [0.13; 1.09] 1.27[0.84; 1.93]CORIMUNO-TOCI-ICU (Group 2), 2020 (REV), Declercq J (COV-AID), 2021 (REV), EU-CTR2020-001375-32 (PreToVid), 0 (REV), EU-CTR2020-001748-24 (ImmCoVA), 0 (REV), NCT04434717 (COVITOZ-1 single dose plus two doses), 0 (REV), NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 (REV), NCT04577534 (COVIDSTORM), 0 (REV), Rutgers, 2021 (REV), Talaschian, 2021 (REV), Veiga, 2021 (REV)1024%1,261moderatelow deathsdetailed resultsCORIMUNO-TOCI-1 (Group 1), 2020 (REV) 1.08 [0.37; 3.19] CORIMUNO-TOCI-ICU (Group 2), 2020 (REV) 1.56 [0.56; 4.40] Declercq J (COV-AID), 2021 (REV) 0.98 [0.38; 2.57] EU-CTR2020-001375-32 (PreToVid), 0 (REV) 1.69 [0.95; 3.04] EU-CTR2020-001748-24 (ImmCoVA), 0 (REV) 0.80 [0.10; 6.22] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 (REV) 1.94 [0.04; 106.66] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 (REV) 14.29 [1.14; 179.57] NCT04577534 (COVIDSTORM), 0 (REV) 2.04 [0.04; 108.96] RCT-TCZ-COVID-19, 2021 (REV) 0.45 [0.04; 5.05] RECOVERY, 2021 (REV) 1.18 [1.06; 1.31] REMAP-CAP (tocilizumab), 2021 (REV) 1.43 [1.05; 1.95] Rutgers, 2021 (REV) 1.61 [0.94; 2.78] Soin AS (COVINTOC), 2021 (REV) 1.49 [0.64; 3.46] Talaschian, 2021 (REV) 0.80 [0.19; 3.29] Veiga, 2021 (REV) 0.37 [0.13; 1.09] 1.21[1.10; 1.33]CORIMUNO-TOCI-1 (Group 1), 2020 (REV), CORIMUNO-TOCI-ICU (Group 2), 2020 (REV), Declercq J (COV-AID), 2021 (REV), EU-CTR2020-001375-32 (PreToVid), 0 (REV), EU-CTR2020-001748-24 (ImmCoVA), 0 (REV), NCT04434717 (COVITOZ-1 single dose plus two doses), 0 (REV), NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 (REV), NCT04577534 (COVIDSTORM), 0 (REV), RCT-TCZ-COVID-19, 2021 (REV), RECOVERY, 2021 (REV), REMAP-CAP (tocilizumab), 2021 (REV), Rutgers, 2021 (REV), Soin AS (COVINTOC), 2021 (REV), Talaschian, 2021 (REV), Veiga, 2021 (REV)150%6,563moderatelow deaths (time to event analysis only)detailed resultsRutgers, 2021 (REV) 1.61 [0.94; 2.78] Talaschian, 2021 (REV) 0.80 [0.19; 3.29] 1.47[0.89; 2.45]Rutgers, 2021 (REV), Talaschian, 2021 (REV)20%394moderatenot evaluable clinical deteriorationdetailed resultsCORIMUNO-TOCI-1 (Group 1), 2020 (REV) 1.79 [0.83; 3.84] RCT-TCZ-COVID-19, 2021 (REV) 0.95 [0.54; 1.69] Soin AS (COVINTOC), 2021 (REV) 1.48 [0.57; 3.88] 1.24[0.82; 1.88]CORIMUNO-TOCI-1 (Group 1), 2020 (REV), RCT-TCZ-COVID-19, 2021 (REV), Soin AS (COVINTOC), 2021 (REV)30%432moderatenot evaluable clinical improvementdetailed resultsDongsheng Wang, 2020 (REV) 0.42 [0.07; 2.48] REMAP-CAP (tocilizumab), 2021 (REV) 0.61 [0.47; 0.80] 0.60[0.46; 0.79]Dongsheng Wang, 2020 (REV), REMAP-CAP (tocilizumab), 2021 (REV)20%820moderatenot evaluable death or ventilationdetailed resultsCORIMUNO-TOCI-1 (Group 1), 2020 (REV) 1.77 [0.76; 4.12] RECOVERY, 2021 (REV) 1.18 [1.08; 1.28] Rutgers, 2021 (REV) 1.54 [1.01; 2.35] Veiga, 2021 (REV) 0.65 [0.28; 1.53] 1.23[0.97; 1.56]CORIMUNO-TOCI-1 (Group 1), 2020 (REV), RECOVERY, 2021 (REV), Rutgers, 2021 (REV), Veiga, 2021 (REV)429%4,168moderatenot evaluable mechanical ventilationdetailed resultsRCT-TCZ-COVID-19, 2021 (REV) 0.74 [0.21; 2.55] Rutgers, 2021 (REV) 1.53 [0.81; 2.89] Soin AS (COVINTOC), 2021 (REV) 0.95 [0.42; 2.16] 1.18[0.74; 1.89]RCT-TCZ-COVID-19, 2021 (REV), Rutgers, 2021 (REV), Soin AS (COVINTOC), 2021 (REV)30%659moderatenot evaluable ICU admissiondetailed resultsRutgers, 2021 (REV) 1.04 [0.60; 1.81] Soin AS (COVINTOC), 2021 (REV) 0.75 [0.38; 1.49] 0.91[0.59; 1.41]Rutgers, 2021 (REV), Soin AS (COVINTOC), 2021 (REV)20%533moderatenot evaluable recoverydetailed resultsTalaschian, 2021 (REV) 1.56 [0.34; 7.13] 1.56[0.34; 7.13]Talaschian, 2021 (REV)10%36NAnot evaluable serious adverse eventsdetailed resultsDongsheng Wang, 2020 (REV) 1.10 [0.02; 57.08] Soin AS (COVINTOC), 2021 (REV) 1.03 [0.47; 2.25] Talaschian, 2021 (REV) 0.13 [0.01; 2.73] Veiga, 2021 (REV) 0.60 [0.22; 1.67] 0.79[0.43; 1.44]Dongsheng Wang, 2020 (REV), Soin AS (COVINTOC), 2021 (REV), Talaschian, 2021 (REV), Veiga, 2021 (REV)40%410moderatenot evaluable adverse eventsdetailed resultsDongsheng Wang, 2020 (REV) 0.10 [0.03; 0.36] Soin AS (COVINTOC), 2021 (REV) 0.67 [0.35; 1.28] Veiga, 2021 (REV) 0.61 [0.30; 1.24] 0.41[0.16; 1.00]Dongsheng Wang, 2020 (REV), Soin AS (COVINTOC), 2021 (REV), Veiga, 2021 (REV)372%374moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-21 11:12 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 651 - roots T: 651

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons